RA MEDICAL SYSTEMS INC (RMED) Stock Price, Quote, News and Overview
NYSEARCA:RMED - NYSE Arca - US74933X3026 - Common Stock - Currency: USD
RMED Quote, Performance and Key Statistics
0.594
+0.05 (+10%)
The current stock price of RMED is 0.594 USD. In the past month the price decreased by -13.28%. In the past year, price decreased by -92.68%.
RMED Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
| ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
| SYK | STRYKER CORP | 31.4 | 145.92B | ||
| MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
| BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
| IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
| DXCM | DEXCOM INC | 53.81 | 34.68B | ||
| RMD | RESMED INC | 26.21 | 34.03B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Related stock screener links
About RMED
Company Profile
Ra Medical Systems, Inc. engages in the design, development and commercialization of excimer lasers for the treatment of vascular immune-mediated inflammatory diseases. The company is headquartered in Fort Mill, South Carolina and currently employs 14 full-time employees. The company went IPO on 2018-09-27. The firm is focused on developing technology for electrophysiology (EP) procedures. The Company’s product includes Ventricular Onset System (VIVO), LockeT and Amigo Remote Catheter System. Its VIVO is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. Its VIVO utilizes non-invasive inputs to locate the origin of ventricular arrhythmias. VIVO uses standard clinical inputs, such as a CT or MRI and a 12 lead ECG, both of which are routinely gathered for EP procedures, allowing VIVO to seamlessly integrate into the workflow. A 3D photograph is obtained of the patient’s torso after the ECG leads are in place and all of these clinical inputs are combined to generate a 3D map of the patient’s heart with a location of the earliest onset of the ventricular arrhythmia.
Company Info
RA MEDICAL SYSTEMS INC
1670 Highway 160 West, Suite 205
Fort Mill SOUTH CAROLINA 92011 US
CEO: Jonathan Will McGuire
Employees: 14
Company Website: https://www.ramed.com/
Phone: 19736912000.0
RA MEDICAL SYSTEMS INC / RMED FAQ
What is the stock price of RA MEDICAL SYSTEMS INC today?
The current stock price of RMED is 0.594 USD. The price increased by 10% in the last trading session.
What is the ticker symbol for RA MEDICAL SYSTEMS INC stock?
The exchange symbol of RA MEDICAL SYSTEMS INC is RMED and it is listed on the NYSE Arca exchange.
On which exchange is RMED stock listed?
RMED stock is listed on the NYSE Arca exchange.
What is the price forecast or stock price prediction for RA MEDICAL SYSTEMS INC stock?
7 analysts have analysed RMED and the average price target is 7.14 USD. This implies a price increase of 1102.02% is expected in the next year compared to the current price of 0.594. Check the RA MEDICAL SYSTEMS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is RA MEDICAL SYSTEMS INC worth?
RA MEDICAL SYSTEMS INC (RMED) has a market capitalization of 4.16M USD. This makes RMED a Nano Cap stock.
How many employees does RA MEDICAL SYSTEMS INC have?
RA MEDICAL SYSTEMS INC (RMED) currently has 14 employees.
What are the support and resistance levels for RA MEDICAL SYSTEMS INC (RMED) stock?
RA MEDICAL SYSTEMS INC (RMED) has a resistance level at 0.62. Check the full technical report for a detailed analysis of RMED support and resistance levels.
Is RA MEDICAL SYSTEMS INC (RMED) expected to grow?
The Revenue of RA MEDICAL SYSTEMS INC (RMED) is expected to grow by 13964.3% in the next year. Check the estimates tab for more information on the RMED EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy RA MEDICAL SYSTEMS INC (RMED) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RMED, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RMED, evaluating the profitability, health, valuation and growth aspects
- RA MEDICAL SYSTEMS INC (RMED) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- RA MEDICAL SYSTEMS INC (RMED) Sales and EPS estimates to see what analysts future expectations are.
- RA MEDICAL SYSTEMS INC (RMED) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- RA MEDICAL SYSTEMS INC (RMED) Insider and Institutional Ownership to learn about the owners and their transactions.
- RA MEDICAL SYSTEMS INC (RMED) Stock Chart to make your own analysis
- RA MEDICAL SYSTEMS INC (RMED) Latest news and press-releases to stay up to date.
Does RA MEDICAL SYSTEMS INC (RMED) stock pay dividends?
RMED does not pay a dividend.
When does RA MEDICAL SYSTEMS INC (RMED) report earnings?
RA MEDICAL SYSTEMS INC (RMED) will report earnings on 2023-11-13.
What is the Price/Earnings (PE) ratio of RA MEDICAL SYSTEMS INC (RMED)?
RA MEDICAL SYSTEMS INC (RMED) does not have a PE ratio as the earnings reported over the last twelve months were negative (-45.97).
RMED Technical Analysis
RMED Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RMED. The financial health of RMED is average, but there are quite some concerns on its profitability.
RMED Financial Highlights
Over the last trailing twelve months RMED reported a non-GAAP Earnings per Share(EPS) of -45.97. The EPS increased by 73.38% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
RMED Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to RMED. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 52.85% and a revenue growth 13964.3% for RMED